78 related articles for article (PubMed ID: 16399439)
1. Vaccines and monoclonal antibodies.
Michaeli D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S82-6. PubMed ID: 16399439
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
3. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
5. TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ; Forero-Torres A; LoBuglio AF
Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
8. Engineered affinity proteins for tumour-targeting applications.
Friedman M; Ståhl S
Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Immunologic targeting: how to channel a minimal response for maximal outcome.
Slovin SF
Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856
[TBL] [Abstract][Full Text] [Related]
12. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.
Marvin JS; Zhu Z
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):184-93. PubMed ID: 16566289
[TBL] [Abstract][Full Text] [Related]
14. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapeutics and apoptosis.
Ludwig DL; Pereira DS; Zhu Z; Hicklin DJ; Bohlen P
Oncogene; 2003 Dec; 22(56):9097-106. PubMed ID: 14663488
[TBL] [Abstract][Full Text] [Related]
17. Eradication of established tumors in mice by a combination antibody-based therapy.
Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
20. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]